SCHEMBL4071129

SCHEMBL4071129

Cc1ccc2cc(C(=O)CC(=O)c3cc(Cl)cc(Cl)c3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 5/20 0.48
KDM4E B2RXH2 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 4/20 0.48
HPGD P15428 3/20 0.48
HTT P42858 2/20 0.48
KCNH2 Q12809 2/20 0.48
PLA2G1B P04054 1/20 0.48
XBP1 P17861 1/20 0.48
ALOX12 P18054 1/20 0.48
ATG4B Q9Y4P1 1/20 0.48
CYP2A6 P11509 2/20 0.47
NPC1 O15118 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13422352 0.88 CYP2A6 (0.58) RAB9APOLBMAPTKDM4EMEN1
SCHEMBL2662882 0.82 HSD17B10 (0.58) RAB9AMAPTKDM4EMEN1KMT2A
SCHEMBL28482006 0.80 CYP2A6 (0.58) RAB9APOLBMAPTKDM4EMEN1
SCHEMBL10456611 0.76 CYP2A6 (0.56) RAB9AMAPTKDM4EMEN1KMT2A
SCHEMBL30253453 0.76 CYP2A6 (0.56) RAB9AMAPTKDM4EMEN1KMT2A
SCHEMBL12532349 0.76 NPC1 (0.68) RAB9AMAPTKDM4EMEN1KMT2A
SCHEMBL9699266 0.76 CYP2A6 (0.66) RAB9APOLBMAPTKDM4EMEN1
SCHEMBL10309477 0.76 POLB (0.43) RAB9APOLBMEN1KMT2ACYP2A6
SCHEMBL10309504 0.76 POLB (0.43) RAB9APOLBMEN1KMT2ACYP2A6
SCHEMBL2758626 0.75 CYP2A6 (0.55) RAB9AKDM4EHPGDCYP2A6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470773-B2 Thiophenes as glucagon receptor antagonists, compositions, and methods for their use MERCK SHARP & DOHME CORP. (US) 2013-06-25 US disclosed
US-20120108505-A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE SCHERING CORPORATION 2012-05-03 US disclosed
WO-2010144664-A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE SCHERING CORPORATION (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108505-A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE GLP1R, GCGR, GPR119 RAB9A 3501/4885POLB 4746/4885MAPT 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.